Hyphens Pharma International Limited
16 Tai Seng Street, Level 4, Singapore 534138
T: (65) 6338 8551 **F:** (65) 6338 8825 **W:** www.hyphensgroup.com
Co. Reg. No.: 201735688C **GST Reg. No.:** 201735688C

Media Release

Hyphens Pharma's Cerapro® MED launches in four European markets

- remederm Cerapro® MED Skin Barrier Cream now reaches patients in Switzerland, Austria, Belgium and the Netherlands through partner Louis Widmer SA
- A first-in-class, non-steroidal cream for the treatment of atopic dermatitis, CE-marked under the European Medical Device Regulation (MDR)

Singapore, 5 November 2026 – Hyphens Pharma International Limited ("**Hyphens Pharma**", "凯帆药剂国际有限公司", or the "**Company**", and together with its subsidiaries, the "**Group**"), Singapore's leading specialty pharmaceutical and consumer healthcare group, today announced that its Cerapro® MED Skin Barrier Cream is now available in Switzerland, Austria, Belgium and the Netherlands through Louis Widmer SA (**"Louis Widmer"**), which markets it as remederm Cerapro® MED Skin Barrier Cream (**"Cerapro® MED"**). The launch follows the licensing, supply and commercialisation agreement between the two companies announced on 5 January 2026.

Atopic dermatitis, the most common form of eczema, affects millions of people of all ages. Elevated skin pH and a weakened skin barrier are key drivers of the condition.

Cerapro® MED is a first-in-class, non-steroidal cream approved in the EU for the treatment of atopic dermatitis. It works by lowering skin pH – the master key in skin barrier homeostasis – which helps restore the skin barrier and supports the skin's natural antimicrobial defences. The product is backed by clinical evidence, including a clinical study conducted in Germany. It is patented in the US, EU and UK.

Louis Widmer will market Cerapro® MED to atopic dermatitis specialists, including dermatologists, paediatricians and allergists, as well as pharmacists. The product made its European scientific debut at the European Academy of Dermatology and Venereology (EADV) Congress in Vienna from 30 September to 3 October 2026.

"The launch of Cerapro® MED extends the reach of our proprietary dermatology portfolio into Europe," said **Mr Lim See Wah（林世华）, Chairman and CEO of Hyphens Pharma.** *"Louis Widmer's experience in dermatology and close relationships with specialists make it a strong partner for this product. Together, we look forward to giving more patients with atopic dermatitis an effective, non-steroidal treatment option."*

"Cerapro® MED gives dermatologists and paediatricians a new, non-steroidal way to treat atopic dermatitis by lowering skin pH for 12 hours. As the new flagship of our remederm range, it builds on our long focus on dry, very dry and atopic skin, and we look forward to working with Hyphens Pharma to bring it to patients across our markets," said **Ms Annemarie Widmer, Owner, President of the Board and CEO of Louis Widmer.**

End.

About Hyphens Pharma International Limited

Hyphens Pharma International Limited and its subsidiaries (the "Group") is Singapore's leading specialty pharmaceutical and consumer healthcare group, driven by the belief that everyone deserves access to a better quality of life.

From its headquarters in Singapore, it maintains a direct presence in Malaysia, Vietnam, Indonesia, Philippines, Thailand and Cambodia, with extended reach into Brunei, Bangladesh, Myanmar, Hong Kong S.A.R. and Oman. Its six key entities — Hyphens Pharma, Pan-Malayan Pharmaceuticals, DocMed Technology, Ocean Health, Novem, and Ardence Aesthetics — collectively advance three core business areas: Pharmaceuticals & Medical Aesthetics, Proprietary Brands, and Digital Platform & E-Pharmacy.

Beyond marketing and distributing specialty pharmaceutical products across selected ASEAN markets through exclusive partnerships with global brand principals, the Group develops and commercialises proprietary dermatological and health supplement products. The Group's integrated ecosystem extends to a medical hypermart and digital pharmacy platform, enabling seamless prescription fulfilment and direct-to-patient medication delivery for healthcare providers.

More information is available at www.hyphensgroup.com.

About Louis Widmer SA

Louis Widmer SA is an international cosmetics and pharmaceuticals company from Switzerland. The family company, with its headquarters in Schlieren, near Zurich, is known for its high-quality skin care and dermatology products. Since it was founded in 1960, Louis Widmer has dedicated itself to sustainability and innovation.

They distinguish themselves by developing, producing, and distributing both pharmaceutical and dermocosmetic products. Their main areas of expertise include dry skin, acne, pigmentation disorders, wound healing, anti-aging, and sun protection, among many others.

More information is available at www.louis-widmer.com.

Issued on behalf of	:	**Hyphens Pharma International Limited**
Media contacts	:	Ms Karina Choo / Mr Gerald Woon / Ms Chong Yi Sze
Email / DID / Mobile	:	karina@cogentcomms.com / (65) 6704 9280 / (65) 9107 6991
		woon@cogentcomms.com / (65) 6704 9268 / (65) 9694 8364
		yisze.chong@hyphens.com.sg / (65) 9729 6694

*This media release has been reviewed by the Company's sponsor, SAC Capital Private Limited (the **"Sponsor"**). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the **"SGX-ST"**) and the SGX-ST assumes no responsibility for the contents of this media release, including*

the correctness of any of the statements or opinions made or reports contained in this media release. The contact person for the Sponsor is Ms Lee Khai Yinn (Tel: (65) 6232 3210) at 1 Robinson Road, #21-01 AIA Tower, Singapore 048542.